October 2018 FDA Recall Drug by Amerigen Pharmaceuticals Inc.
D-0249-2019 - Failed dissolution specifications

This Class III drug recall was voluntarily initiated by Amerigen Pharmaceuticals Inc. on October 5, 2018 for the product Drug. The FDA reported the reason for recall as failed dissolution specifications. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-0249-2019

Reason for Recall
Failed dissolution specifications: Out-of-Specification dissolution results obtained during stability testing.
Initiated
10-05-2018
Reported
10-24-2018
Quantity
5,232 bottles: a) 4,146 bottles; b) 1,086 bottles

Recall Profile & Regulatory Data

Class III - is a situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences.
Amerigen Pharmaceuticals Inc.
Product was distributed U.S. nationwide.
Temozolomide capsules, 20 mg, packaged in a) 5-count bottle(NCD 43975-253-05), b) 14-count bottle (NDC 43975-253-14), Rx only, Mfd. by: Stason Pharmaceuticals, Inc., Irvine, CA 92618, Dist. By: Amerigen Pharmaceuticals, Lyndhurst, NJ 07071.

Batch or Lot Expiration Information

Lot# : a) 17F058A, Exp 6/19; b) 17F058B, Exp 6/19